AccueilLXRX • NASDAQ
add
Lexicon Pharmaceuticals
2,39 $
Après la clôture :(0,42 %)+0,0100
2,40 $
Fermé : 26 juil., 18:18:34 UTC−4 · USD · NASDAQ · Clause de non-responsabilité
Dernière clôture
2,33 $
Variation sur la journée
2,32 $ - 2,44 $
Plage sur l'année
0,92 $ - 3,73 $
Capitalisation boursière
863,85 M USD
Volume moyen
3,01 M
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
NASDAQ
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (USD) | mars 2024info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | 1,13 M | 4 608,33 % |
Charges d'exploitation | 32,06 M | 67,50 % |
Résultat net | -48,40 M | -51,55 % |
Marge bénéficiaire nette | -4,28 k | 96,78 % |
Bénéfice par action | -0,20 | -17,65 % |
EBITDA | -45,19 M | -45,63 % |
Taux d'imposition effectif | — | — |
Bilan
Total des actifs
Total du passif
| (USD) | mars 2024info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 355,60 M | 235,67 % |
Total des actifs | 417,22 M | 156,41 % |
Total du passif | 128,35 M | 71,89 % |
Total des capitaux propres | 288,87 M | — |
Actions en circulation | 246,24 M | — |
Ratio cours/valeur comptable | 1,99 | — |
Rentabilité des actifs | -35,05 % | — |
Retour sur capitaux | -38,14 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (USD) | mars 2024info | Variation Y/Y |
|---|---|---|
Résultat net | -48,40 M | -51,55 % |
Trésorerie (opérations) | -55,13 M | -74,39 % |
Trésorerie (invest.) | -110,22 M | -1 011,47 % |
Trésorerie (financement) | 239,38 M | 29 151,33 % |
Variation nette en trésorerie | 74,03 M | 463,89 % |
Flux de trésorerie dispo. | -37,14 M | -77,19 % |
À propos
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
CEO
Date de fondation
1995
Site Web
Employés
285
